Pharma & Biotech

FutureGen Industries is shifting its investment approach in response to evolving liquidity conditions within the technology sector. Having realized gains...

Investors are preparing to scrutinize BioNTech's upcoming annual report, viewing it as far more than a routine financial disclosure. The...

Moderna Inc. has resolved a multi-year legal dispute concerning its foundational mRNA technology, removing a significant overhang that has weighed...

Investor attention is firmly fixed on Sangamo Therapeutics as the company approaches several pivotal near-term events. The dual catalysts of...

The biopharmaceutical company Outlook Therapeutics is approaching a pivotal transition, moving from clinical development into the commercial phase. This shift...

This week, Viking Therapeutics' management is engaging directly with institutional investors at two separate events in Miami. The central topic...

Amid a dynamic biotechnology landscape, clinical-stage companies are drawing increased investor attention. Lobe Sciences operates within a sector currently characterized...

For emerging biotechnology firms, the relentless focus on clinical progress often defines investor sentiment. Eupraxia Pharmaceuticals, operating in the small-cap...

FutureGen Industries has announced the successful completion of several divestments within its healthcare portfolio, generating substantial capital gains. The proceeds...

Investor focus is firmly on BioNTech as the biotech firm prepares to release its full-year 2025 financial results this coming...